Health Now

FDA allows 1st rapid coronavirus test that gives results at home

Associated Press
By Associated Press
2 Min Read Nov. 17, 2020 | 5 years Ago
Go Ad-Free today

WASHINGTON — U.S. regulators on Tuesday allowed emergency use of the first rapid coronavirus test that can be performed and developed entirely at home.

The announcement by the Food and Drug Administration represents an important step in U.S. efforts to expand testing options for covid-19 beyond health care facilities and testing sites. However, the test will require a prescription, likely limiting its initial use.

The FDA granted emergency authorization to the 30-minute test kit from Lucira Health, a California manufacturer.

The company’s test allows users to swab themselves to collect a nasal sample. The sample is then swirled in a vial that plugs into a portable device, that interprets the results and displays whether the person tested positive or negative for coronavirus.

To date, the agency has authorized nearly 300 tests for coronavirus. The vast majority require a nasal swab performed by a health professional and must be processed at laboratories using high-tech testing equipment. A handful allow people to collect their own sample at home — a nasal swab or saliva — that’s then shipped to a lab, which usually means waiting days for results.

Health experts have for months called for options to allow people to test themselves at home, reducing turnaround times and the potential spread of the virus to health care workers.

Lucira did not immediately respond to request for additional details.

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options